A short treatment with galactomannan GM-CT-01 corrects the functions of freshly isolated human tumor-infiltrating lymphocytes

PURPOSE:

Several galectins are released by tumor cells and macrophages and accumulate in the tumor microenvironment. Galectin-1 and -3 were found to bind to glycosylated receptors at the surface of tumor-infiltrating lymphocytes (TIL), forming glycoprotein-galectin lattices that could reduce the motility and therefore the functionality of surface molecules. In contrast to blood T cells, human TIL show defective IFN-g secretion upon ex vivo stimulation. We have previously shown that extracellular galectin-3 participates in the impairment of TIL functions. Indeed, disruption of glycoprotein-galectin-3 lattices using anti-galectin-3 antibodies, or N-acetyllactosamine as a competing sugar, boosted cytokine secretion by TIL. Here we have tested a clinical grade galectin antagonist: GM-CT-01, a galactomannan obtained from guar gum reported to be safe in more than 50 cancer patients.
EXPERIMENTAL DESIGN:

TIL were isolated from human tumor ascites, treated for 2-20 h with galectin antagonists and tested for function.
RESULTS:

We found that GM-CT-01 boosts cytotoxicity of CD8+ TIL and their IFN-g secretion in a dose-dependent manner. Treating TIL obtained from patients with various cancers, during a few hours, resulted in an increased IFN-g secretion in up to 80% of the samples.
CONCLUSIONS:

These observations pave the way for investigating the potential benefit of this galectin antagonist in cancer patients, alone or combined with cancer vaccination, in order to correct in vivo impaired functions of TIL.